Cardiff Oncology Stock Declines in the Last Trading Day
Cardiff Oncology Inc. (CRDF) experienced a modest decline of 1.06 % during the 24‑hour period concluding at 10:58 AM Central Europe time on Friday, 23 October 2026. The share price currently trades at approximately USD 0.93 on the Nasdaq exchange.
Market Overview
- Current Market Capitalisation: USD 73.1 million
- Outstanding Shares: 68.4 million
- Volume Traded in Last 24 Hours: USD 212.7 k
- Year‑to‑Date Performance: Since the end of September, the stock has fallen 29.01 %.
- 200‑Day Simple Moving Average: USD 1.50
- 52‑Week High/Low: USD 3.31 on 26 December 2025; USD 0.76 on 29 July 2026
The recent decline aligns with broader market softness in the biotechnology sector, where investors are exercising caution amid regulatory uncertainties and the cyclical nature of drug development pipelines.
Peer Performance
The following table summarizes the performance of comparable oncology and biotech stocks during the same 24‑hour period:
| Ticker | Movement | Current Price | Market Cap | Key Metric |
|---|---|---|---|---|
| /The (LGL) | –2.35 % | USD 6.65 | USD 86 million | P/E = 274.43 |
| Tenaya Therapeutics (TNYA) | –4.88 % | USD 0.39 | USD 87.5 million | – |
| Telyrx (TELY.TO) | 0 % | CAD 2.35 | CAD 122.1 million | – |
| Rallybio (RLYB) | –0.98 % | USD 16.4 | USD 86.2 million | P/E = 2.06 |
| Ebr (EBR.AX) | –3.45 % | AUD 0.14 | AUD 122.6 million | – |
While Cardiff Oncology’s decline is modest relative to its peers, it is noteworthy that Tenaya Therapeutics and Ebr experienced sharper drops, reflecting sector‑wide volatility.
Company Profile
Cardiff Oncology Inc. is headquartered in San Diego, United States, and focuses on the development of therapeutic solutions for solid tumors and hematologic malignancies. The company’s research pipeline includes innovative drug candidates that target key molecular pathways implicated in cancer progression. Cardiff Oncology’s mission centers on delivering novel treatments to patients across California, with a broader vision of impacting the global oncology landscape.
For further information about Cardiff Oncology’s products, clinical programs, and corporate governance, interested parties may visit the company’s website at www.cardiffoncology.com .
This article is intended for informational purposes and does not constitute investment advice.
